[ET Net News Agency, 22 December 2021] TOT BIOPHARM International Company Limited
(01875) said TOT BIOPHARM Co., Ltd. (TOT Suzhou), a wholly-owned subsidiary of the
company, has entered into an exclusive promotion service agreement with Jiangxi Jixin
Pharmaceutical Co., Ltd. (as the promotion service provider, Jixin Pharmaceutical), a
wholly-owned subsidiary of Jiangxi Jimin Kexin Pharmaceutical Industry Investment Co.,
Ltd. (Jimin Kexin Pharmaceutical), in respect of the marketing of bevacizumab injection
(intended English trade name: Pusintin) in mainland China (excluding Hong Kong, Macau and
Taiwan regions) (the promotion service area), pursuant to which Jixin Pharmaceutical will
enjoy the exclusive promotion right in respect of the product in the promotion service
area, while TOT Suzhou will continue to possess all the rights and interests in respect of
the product in the promotion service area other than promotion right.
The product is a biological antibody drug self-developed by TOT Suzhou, which has
obtained the marketing approval from the National Medical Products Administration of China
recently and is used for the treatment of advanced, metastatic or recurrent non-squamous
non-small-cell lung cancer (nsNSCLC) and metastatic colorectal cancer (mCRC). (RC)